Urology
News, opinions and meeting coverage in urology.
— Results from interim analysis suggest "potential to disrupt the NMIBC treatment landscape"
Latest in Urology
Investigational intravesical solution led to complete response rate of 79%
Study validates concerns about benign prostatic hyperplasia-related PSMA-PET false positives
Potential standard of care after current therapies, but key obstacles remain in the way
Building on recent success requires intervention at multiple steps in the cancer immunity cycle
Potential standard of care after current therapies, but key obstacles remain in the way
Building on recent success requires intervention at multiple steps in the cancer immunity cycle
More in Urology
Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients
Grade 3 or higher neutropenia, neutropenic complications reduced by 12-fold
Time to radiographic progression doubled with 177Lu-PSMA-617
After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus
Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy
Also in TTHealthWatch: reducing infections in joint replacement
It's time for clear guidelines
One dose proved noninferior to triple-dose regimen in randomized trial
Complete clinical response predicted favorable outcomes for up to 2 years
Treatment over 1 to 2 weeks achieves similar outcomes to therapy given for as long as 7.5 weeks
Nedosiran approved for patients ages 9 years and older with primary hyperoxaluria type 1
Combination improved biochemical response and PFS compared with systemic treatment alone
